This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

MAGIC Cell-5-Combicytokine Trial (MAGIC Cell-5)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2007 by Seoul National University Hospital.
Recruitment status was:  Recruiting
Information provided by:
Seoul National University Hospital Identifier:
First received: July 13, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted
Combination use of darbepoetin and G-CSF will improve left ventricular systolic function in patients with acute myocardial infarction who receive intracoronary infusion of mobilized peripheral blood stem cell in comparison with patient who treated with conventional measures and who received intracoronary infusion of mobilized peripheral blood stem cell by G-CSF alone.

Condition Intervention Phase
Acute Myocardial Infarction Drug: G-CSF with/without darbepoetin, peripheral blood stem cell infusion Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Single Center, Prospective, Randomized, Partly-Double Blinded, Controlled Trial to Assess the Safety and Feasibility of Intracoronary Cell Infusion Mobilized With G-CSF and Darbepoetin and Their Effects on Improvement of Cardiac Function in Patients With Myocardial Infarction: Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Erythropoietin Mobilization and Intra-Coronary Cell Infusion –5-Combination Cytokine Therapy Trial

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • change of left ventricular ejection fraction measured by cardiac MRI [ Time Frame: 6, 12, and 24month ]

Secondary Outcome Measures:
  • wall motion score index exercise capacity BNP [ Time Frame: 6,12, 24month ]

Estimated Enrollment: 116
Study Start Date: March 2007
Estimated Study Completion Date: February 2010

Ages Eligible for Study:   15 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ST elevation acute myocardial infarction
  • < 80years
  • successful revascularization of culprit vessel

Exclusion Criteria:

  • uncontrolled congestive heart failure
  • uncontrolled myocardial ischemia
  • uncontrolled ventricular arrhythmia
  • malignancy
  • serious hematologic disease
  • chronic renal failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00501917

Contact: Hyo-Soo Kim, MD PhD 82-2-2072-2226
Contact: Hyun-Jae Kang, MD PhD 82-2-2072-2279

Korea, Republic of
Seoul National Univesity Hospital Recruiting
Seoul, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Hyo-Soo Kim, MD PhD Seoul National University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00501917     History of Changes
Other Study ID Numbers: MAGIC Cell-5
Study First Received: July 13, 2007
Last Updated: July 13, 2007

Keywords provided by Seoul National University Hospital:
acute myocardial infarction

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Darbepoetin alfa
Hematinics processed this record on September 21, 2017